[go: up one dir, main page]

HRP980203B1 - Modified tnf "alpha" molecules, dna encoding such modified tnf "alpha" molecules and vaccines comprising such modified tnf "alpha" molecules and dna - Google Patents

Modified tnf "alpha" molecules, dna encoding such modified tnf "alpha" molecules and vaccines comprising such modified tnf "alpha" molecules and dna

Info

Publication number
HRP980203B1
HRP980203B1 HR980203A HRP980203A HRP980203B1 HR P980203 B1 HRP980203 B1 HR P980203B1 HR 980203 A HR980203 A HR 980203A HR P980203 A HRP980203 A HR P980203A HR P980203 B1 HRP980203 B1 HR P980203B1
Authority
HR
Croatia
Prior art keywords
alpha
molecules
tnfalpha
modified tnf
modified
Prior art date
Application number
HR980203A
Other languages
English (en)
Inventor
Martin
Soren Mouritsen
Henrik Elsner
Iben Dalum
Original Assignee
Ferring Farma Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Farma Lab filed Critical Ferring Farma Lab
Publication of HRP980203A2 publication Critical patent/HRP980203A2/hr
Publication of HRP980203B1 publication Critical patent/HRP980203B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/144—Tumor necrosis factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HR980203A 1997-04-15 1998-04-15 Modified tnf "alpha" molecules, dna encoding such modified tnf "alpha" molecules and vaccines comprising such modified tnf "alpha" molecules and dna HRP980203B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK41897 1997-04-15

Publications (2)

Publication Number Publication Date
HRP980203A2 HRP980203A2 (en) 1998-12-31
HRP980203B1 true HRP980203B1 (en) 2003-04-30

Family

ID=8093298

Family Applications (1)

Application Number Title Priority Date Filing Date
HR980203A HRP980203B1 (en) 1997-04-15 1998-04-15 Modified tnf "alpha" molecules, dna encoding such modified tnf "alpha" molecules and vaccines comprising such modified tnf "alpha" molecules and dna

Country Status (29)

Country Link
US (1) US7118750B1 (pl)
EP (1) EP0975668B1 (pl)
JP (1) JP2001521386A (pl)
KR (1) KR100522289B1 (pl)
CN (1) CN1178955C (pl)
AR (1) AR012427A1 (pl)
AT (1) ATE326481T1 (pl)
AU (1) AU743400B2 (pl)
BR (1) BR9811462A (pl)
CA (1) CA2289476A1 (pl)
CZ (1) CZ9903657A3 (pl)
DE (1) DE69834556T2 (pl)
DK (1) DK0975668T3 (pl)
EE (1) EE9900461A (pl)
ES (1) ES2264569T3 (pl)
HR (1) HRP980203B1 (pl)
HU (1) HUP0001930A3 (pl)
IL (1) IL132281A0 (pl)
NO (1) NO995002L (pl)
NZ (1) NZ337955A (pl)
PL (1) PL194221B1 (pl)
RU (1) RU2241715C2 (pl)
SI (1) SI0975668T1 (pl)
SK (1) SK285639B6 (pl)
TR (1) TR199902562T2 (pl)
TW (1) TW510921B (pl)
UA (1) UA72440C2 (pl)
WO (1) WO1998046642A1 (pl)
ZA (1) ZA983148B (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
CA2364026C (en) * 1999-03-02 2012-08-21 Centocor, Inc. Anti-tnf.alpha. antibodies in therapy of asthma
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
WO2000067777A1 (en) * 1999-05-07 2000-11-16 Biofan Pty Ltd A method of prophylaxis and treatment and agents useful therefor
CN1384757A (zh) 1999-07-20 2002-12-11 法麦克萨有限公司 下调gdf－8活性的方法
EP1296709A1 (en) * 2000-06-21 2003-04-02 Ferring BV Solubilised protein vaccines
AU2003208314A1 (en) * 2002-03-11 2003-09-22 Pharmexa A/S Novel application of vaccination against tnf-alpha
FR2844514B1 (fr) * 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
WO2004069182A2 (en) * 2003-02-01 2004-08-19 Neuralab Limited Active immunization to generate antibodies to soluble a-beta
WO2005084198A2 (en) 2004-02-27 2005-09-15 Vaxconsulting Peptides of il1 beta and tnf alpha and method of treatment using same
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
EP2500037A3 (en) 2005-05-16 2012-10-24 Abbott Biotechnology Ltd Use of TNF alpha inhibitor for treatment of erosive polyarthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
BRPI0817705A2 (pt) * 2007-09-25 2015-03-31 Intervet Int Bv Vacina para o tratamento de osteoatrite em um vertebrado, uso de citocinas il-ibeta e opcionalmente inf-alfa, e, tratamento de osteoartrite em um vertebrado.
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CN102666588A (zh) 2009-11-05 2012-09-12 Uab研究基金会 治疗基底细胞样基因型癌症
US8703712B2 (en) 2010-03-18 2014-04-22 The Uab Research Foundation Targeting cancer stem cells with DR5 agonists
US8907053B2 (en) * 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
JP2014500267A (ja) 2010-12-08 2014-01-09 ネオヴァクス 強力に不活性化されているがなお高い免疫原性を示すワクチンおよびその製造方法
EP2462950A1 (en) 2010-12-08 2012-06-13 Neovacs Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
CN102539778A (zh) * 2010-12-24 2012-07-04 北京义翘神州生物技术有限公司 一种检测人肿瘤坏死因子-α的酶联免疫试剂盒
JP2011201902A (ja) * 2011-05-19 2011-10-13 Wyeth Llc 可溶性Ａ−βに対する抗体を生成させるための能動免疫
CN103376327A (zh) * 2012-04-28 2013-10-30 通用电气公司 检测抗体或融合蛋白的浓度的方法
DK3292140T3 (en) 2015-05-05 2022-05-23 Rubicon Biotechnology Llc Immunterapeutikum mod cancer
CN106279403B (zh) * 2016-08-16 2019-06-11 长春市海兰深生物医学技术有限公司 一种检测天然肺癌相关抗体的组合物、试剂盒和方法
CN106478802B (zh) * 2016-10-11 2019-08-09 浙江省人民医院 TNF-α蛋白B细胞表位，含此表位的多抗原肽及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE107362T1 (de) * 1986-06-20 1994-07-15 Dainippon Pharmaceutical Co Polypeptid-mutanten des menschlichen tnf und für diese mutanten codierende dns.
DE3843534A1 (de) * 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
AU634379B2 (en) 1991-04-29 1993-02-18 Csl Limited Recombinant immunocastration vaccine
SE9102808L (sv) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
CA2119089A1 (en) * 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden

Also Published As

Publication number Publication date
DE69834556D1 (de) 2006-06-22
ATE326481T1 (de) 2006-06-15
HRP980203A2 (en) 1998-12-31
AU743400B2 (en) 2002-01-24
US7118750B1 (en) 2006-10-10
SI0975668T1 (sl) 2007-02-28
CA2289476A1 (en) 1998-10-22
WO1998046642A1 (en) 1998-10-22
KR20010006416A (ko) 2001-01-26
HK1022918A1 (en) 2000-08-25
TR199902562T2 (xx) 2000-02-21
HUP0001930A3 (en) 2001-10-29
NO995002L (no) 1999-12-15
TW510921B (en) 2002-11-21
NZ337955A (en) 2000-09-29
CZ9903657A3 (cs) 2001-09-12
PL194221B1 (pl) 2007-05-31
SK140999A3 (en) 2000-06-12
JP2001521386A (ja) 2001-11-06
ZA983148B (en) 1999-10-15
DE69834556T2 (de) 2007-05-10
PL336295A1 (en) 2000-06-19
RU2241715C2 (ru) 2004-12-10
EP0975668A1 (en) 2000-02-02
UA72440C2 (en) 2005-03-15
CN1252809A (zh) 2000-05-10
EE9900461A (et) 2000-06-15
AR012427A1 (es) 2000-10-18
CN1178955C (zh) 2004-12-08
DK0975668T3 (da) 2006-09-25
KR100522289B1 (ko) 2005-10-19
IL132281A0 (en) 2001-03-19
ES2264569T3 (es) 2007-01-01
AU7030398A (en) 1998-11-11
BR9811462A (pt) 2000-09-12
HUP0001930A2 (hu) 2000-09-28
SK285639B6 (sk) 2007-05-03
EP0975668B1 (en) 2006-05-17
NO995002D0 (no) 1999-10-14

Similar Documents

Publication Publication Date Title
HRP980203B1 (en) Modified tnf "alpha" molecules, dna encoding such modified tnf "alpha" molecules and vaccines comprising such modified tnf "alpha" molecules and dna
BG102343A (en) Recombinant anti-cd4 antibodies for therapy in hyman medicine
DE60332645D1 (de) Ii-key/antigene epitop-hybrid-peptid-vakzine
NZ508381A (en) Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
AU5376201A (en) Methods and compositions for impairing multiplication of hiv-1
BR9408006A (pt) Molécula de ácido nucléico isolada e purificada vetor e vetor de express o adaptados para transformaçao de hospedeiro hospedeiro transformado proteina receptora "transferrin" recombinante ou fragmento ou análogo da mesma proteina Tbpl purificada e isolada proteina Tbp2 purificada e isolada peptídeo composiç o imunogênica vetor ativo para fornecimento de proteina receptora "transferrin" vetor de plasmideo linhagem de haemophilus processo para produzir proteina Tbp2 ou Tbpl purificada e isolada
ES2241040T3 (es) Proteinas hibridas que forman heterodimeros.
NZ333203A (en) Tumour antigen proteins, genes thereof, and tumour antigen peptides
ATE371671T1 (de) Rekombinantes allergen, seine fragmente und die damit korrespondierenden dna-moleküle, vektoren, und diese dna-moleküle enthaltenden wirte, und dignostische und therapeutische verwendungen besagter allergene und fragmente
IL93397A (en) Pancreatic islet cell antigen protein or peptides, their preparation by molecular cloning, their use in the diagnosis of insulin dependent diabetes mellitus and pharmaceutical compositions comprising said antigens
JPH05506247A (ja) ヒトγインターフェロンのアンタゴニスト
AU5776799A (en) Modified hcv peptide vaccines
PT93178B (pt) Agente proteico anticanceroso
EP1277837A3 (de) Epididymis-spezifische DNA-Sequenzen und deren Verwendung
CA2006587A1 (en) Membrane proteins and peptides of haemophilus influenzae type b
KR930703444A (ko) 어류 황체화 호르몬-방출 호르몬 동족체
Fischer et al. Synthetic peptide antigens of tetanus toxin
EP0662150A4 (en) MASPIN, NEW SERPIN WITH ANTI-TUMOR ACTIVITY.
NZ505350A (en) DNA encoding a tumour antigen peptide (43 kDa) for diagnosis or treatment of tumours
AU2001281943A1 (en) The t-cell protein (tzon7), peptides and antibodies derived therefrom and uses thereof
CA1328840C (en) Fibroblast growth factor antagonists
JPS61100598A (ja) 抗原性ペプチド化合物
WO2002010379B1 (en) Modified cea and uses thereof
GEP20002244B (en) Osteoprotegerin
AR036104A1 (es) Un receptor acoplado a la proteina g, gave3

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
PPPP Transfer of rights

Owner name: PHARMEXA A/S, DK

ODRP Renewal fee for the maintenance of a patent

Payment date: 20070223

Year of fee payment: 10

PBON Lapse due to non-payment of renewal fee

Effective date: 20080416